Bezlotoxumab beats placebo at preventing recurrent C. difficile infections in high-risk patients

SAN DIEGO – Bezlotoxumab prevented recurrent Clostridium difficile infections (CDIs) among high-risk patients even more effectively than in the overall populations of the placebo-controlled...
Source: Family Practice News - Category: Primary Care Source Type: news